Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Preclinical Development of a Zinc Finger Transcriptional Repressor Targeting the SCN9A Gene as a Novel Therapy for Peripheral Neuropathic Pain

Download PDF